Results 191 to 200 of about 135,991 (315)

Ictal semiology in precuneus seizures: A systematic review

Epileptic Disorders, EarlyView.
Abstract Objective To evaluate the ictal semiology in seizures originating in the precuneus and to help guide seizure interpretation within the framework of presurgical evaluation. Methods This systematic review followed a Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) and a Quality Assessment tool for Diagnostic Accuracy ...
Erika Ignatius, Liisa Metsähonkala, Henna Jonsson, Leena Lauronen, Päivi Nevalainen, Jukka Vanhanen, Juha Wilenius, Georg Zimmermann, Maria Peltola   +8 more
wiley   +1 more source

Real-world outcomes of ustekinumab, vedolizumab, and tumor necrosis factor inhibitors in very-early-onset inflammatory bowel disease: a multi-center cohort study. [PDF]

J Gastroenterol
Nambu R, Iwama I, Takeuchi I, Hagiwara SI, Etani Y, Kaji E, Yoden A, Kakuta F, Hoshi Y, Tsumura N, Mizuochi T, Kumagai H, Yokoyama K, Nishizawa T, Usami M, Takaki Y, Ebana R, Kurasawa S, Fujikawa H, Ishige T, Kudo T, Yoshida MM, Shimizu H, Arai K.   +23 more
europepmc   +1 more source

Effectiveness and safety of cenobamate after conversion to monotherapy or dual therapy in real‐world clinical practice

Epileptic Disorders, EarlyView.
Abstract Objective Patients with drug‐resistant epilepsy (DRE) typically take multiple anti‐seizure medications (ASMs) and are at risk of treatment‐related adverse events (AEs). This study assessed the impact of cenobamate monotherapy or dual therapy in patients with drug‐resistant epilepsy.
Álvaro Sánchez‐Guijo Benavente, Guillermina García Martín, Estuardo Daniel Castro Ruiz, Pablo Cabezudo García, Yolanda López Moreno, José Carlos Estévez María, Irene Lorite Fuentes, Sergio Navarro Conti, Raquel Calle Calle, Alejandro Fernández Cabrera, Isabel Ros González, Dulce Campos Blanco, María Isabel Chamorro Muñoz, Pedro Jesús Serrano Castro   +13 more
wiley   +1 more source

Nivolumab for unresectable cutaneous epithelial malignancies: an open-label, single-arm, multi-centre, phase II trial (NMSC-PD1). [PDF]

BMC Cancer
Nakamura Y, Yamazaki N, Namikawa K, Uchi H, Mori S, Ogawa-Momohara M, Fujimura T, Takenouchi T, Kurimoto M, Yamamoto Y, Otsuka A, Kabashima K, Fusumae T, Hirai I, Tanese K, Saito Y, Amagai M, Takemura R, Sato Y, Funakoshi T.   +19 more
europepmc   +1 more source

The outcomes of consecutive pregnancies in Australian women with epilepsy

Epileptic Disorders, EarlyView.
Abstract Objective To investigate the extent to which seizure control and the occurrence of fetal malformation in an initial pregnancy can serve to anticipate the outcome in the next pregnancy. Methods We analyzed the records of the Raoul Wallenberg Australian Register of Antiepileptic Drugs in Pregnancy for seizure control and fetal malformation data ...
Frank Vajda, Terence J. O'Brien, Janet Graham, Alison Hitchcock, Piero Perucca, Cecilie Lander, Simon Vajda, Mervyn Eadie   +7 more
wiley   +1 more source

Evolving phase I oncology trials in the precision medicine era: design, outcomes, and geographic access. [PDF]

ESMO Real World Data Digit Oncol
Katsuya Y, Koyama T, Sato J, Okada M, Yamamoto N.   +4 more
europepmc   +1 more source

Evolution of the European Medicines Agency clinical guidelines for epilepsy drug development between 2010 and 2025: A comparative analysis by the ILAE Task Force on Regulatory Affairs

Epilepsia, EarlyView.
Abstract Objective The latest European Medicines Agency (EMA) guideline on the clinical investigation of medicines to treat epileptic disorders was adopted by the EMA Committee for Medicinal Products for Human Use in 2025. We compared this guideline with the previous version (2010), highlighting areas where significant revisions were introduced ...
Stéphane Auvin, Alexis Arzimanoglou, Jacqueline French, Kelly G. Knupp, Lieven Lagae, Eugen Trinka, Dennis Dlugos, Emilio Perucca   +7 more
wiley   +1 more source

Clinical development of molecular residual disease (MRD) and multi-cancer early detection (MCED) using liquid biopsy multiomics with artificial intelligence (AI). [PDF]

Int J Clin Oncol
Shibuki T, Yamashita R, Hashimoto T, Fujisawa T, Imai M, Yuda J, Kuwata T, Misumi T, Nakamura Y, Bando H, Kojima K, Tokioka S, Chiba I, Nakaya N, Hozawa A, Koshiba S, Fuse N, Saito S, Shimizu R, Park WY, Kinoshita K, Yoshino T.   +21 more
europepmc   +1 more source

Stiripentol: Unpublished results from the first phase 2 clinical trial in Lennox–Gastaut syndrome conducted in the early 1990s

Epilepsia, EarlyView.
Abstract Objective This study was undertaken to present the results of an exploratory phase 2 trial of stiripentol in Lennox–Gastaut syndrome (LGS). Methods This exploratory single‐blind, single‐arm, nonrandomized sequential‐period phase 2 study was conducted at four centers in France between January 1989 and August 1993.
Stéphane Auvin, Benjamin Serraz, Jérémie Lespinasse, Laurent Chancharme   +3 more
wiley   +1 more source

Cerebrospinal fluid ctDNA clarifies clonal divergence: leptomeningeal flare of <i>EGFR</i>-mutant disease after switch to selpercatinib for acquired <i>RET</i> fusion. [PDF]

J Liq Biopsy
Kunimasa K, Tamiya M, Inoue T, Mamesaya N, Tanaka T, Komuta K, Futamura S, Honma K, Nishino K.   +8 more
europepmc   +1 more source